Hyperkalemia in acute glomerulonephritis due to transient hyporeninemic hypoaldosteronism.
Transient hyperkalemia has been reported to occur in patients with acute glomerulonephritis, but the pathogenetic mechanism has not been investigated systematically. We studied the mechanism of hyperkalemia (5.7 to 6.7 mmol/liter) in four men with post-infectious glomerulonephritis. All four patients had clinical findings consistent with acute glomerulonephritis (edema, hypertension, proteinuria, hematuria, and an elevated ASO titer) and a renal biopsy performed in three of the patients confirmed the diagnosis. In comparison to normal subjects (N = 18), plasma aldosterone (5.4 +/- 1.6 vs. 22.8 +/- 2.6 ng/dl, P less than 0.005) and plasma renin activity (0.3 +/- 0.2 vs. 4.3 +/- 0.6 ng/ml/hr, P less than 0.005) were reduced. Hyperkalemia resolved within one to two weeks in two patients as the nephritis resolved and diuresis ensued, and aldosterone and renin levels obtained at follow-up visits were normal. Hyperkalemia persisted despite furosemide-induced diuresis in the other two patients, but resolved with fludrocortisone treatment. Thus, hyperkalemia in patients with acute glomerulonephritis is a manifestation, in part, of hyporeninemic hypoaldosteronism. It is ameliorated by mineralocorticoid therapy and improves spontaneously with resolution of the glomerulonephritis.
Don
B R
BR
Medical Service, San Francisco General Hospital Medical Center, California.
Schambelan
M
M
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D005438:Fludrocortisone / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000150:complications*; D006801:Humans; D006947:Hyperkalemia / Q000188:drug therapy / Q000209:etiology*; D006994:Hypoaldosteronism / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D012084:Renin-Angiotensin System / Q000502:physiology
D005665:Furosemide; D005438:Fludrocortisone